Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $24.00 per share, before underwriting discounts. Intellia also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be $150 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Intellia. Credit Suisse, Jefferies LLC, and Leerink Partners are acting as joint book-running managers of the offering. The offering is expected to close on or about November 6, 2017, subject to
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.MarketBeat
- 2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 4/22/24 - Form 3
- 4/16/24 - Form PRE
- 4/15/24 - Form 8-K
- NTLA's page on the SEC website